Time to death from prostate cancerMedian · advanced hormone‐sensitive prostate cancer
Early probably leads to lower time to death from prostate cancer (here: prostate cancer mortality… compared with deferred AST (moderate certainty).
1 finding from 1 review
Skeletal events · advanced hormone‐sensitive prostate cancer
Early may leads to lower skeletal events compared with deferred AST (low certainty).
1 finding from 1 review
Fatigue · advanced hormone‐sensitive prostate cancer
Early may leads to higher fatigue compared with deferred AST (low certainty).
1 finding from 1 review
Heart failure · advanced hormone‐sensitive prostate cancer
Early may leads to higher heart failure compared with deferred AST (low certainty).
1 finding from 1 review
Global quality of life · advanced hormone‐sensitive prostate cancer
1 finding from 1 review
Stone expulsion time · adult patients presenting with symptoms of ureteral stone disease
1 finding from 1 review
Pain episodes · adult patients presenting with symptoms of ureteral stone disease
1 finding from 1 review
Dose of diclofenac (mg) · adult patients presenting with symptoms of ureteral stone disease
1 finding from 1 review
Hospital admissions · adult patients presenting with symptoms of ureteral stone disease
Alpha‐blockers showed no clear difference in hospitalisation compared with placebo (moderate certainty).
1 finding from 1 review
Surgical intervention · adult patients presenting with symptoms of ureteral stone disease
Alpha‐blockers showed no clear difference in surgical intervention compared with placebo (high certainty).
1 finding from 1 review
Stone clearance · adult patients presenting with symptoms of ureteral stone disease
Alpha‐blockers probably leads to higher stone clearance compared with placebo (moderate certainty).
1 finding from 1 review
Major adverse events · adult patients presenting with symptoms of ureteral stone disease
Alpha‐blockers probably leads to higher major adverse events compared with placebo (moderate certainty).
1 finding from 1 review
1‐year mortality · previously untreated patients with mRCC
Interferon‐α alone probably leads to higher 1‐year mortality compared with standard targeted therapies (sunitinib or temsirolimus) (moderate certainty).
1 finding from 1 review
1‐year mortality · previously untreated patients with mRCC
Interferon‐α alone showed no clear difference in 1‐year mortality compared with interferon‐α plus bevacizumab (low certainty).
1 finding from 1 review
Quality of life · previously untreated patients with mRCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α alone probably leads to lower adverse events (grade ≥ 3) compared with interferon‐α plus bevacizumab (moderate certainty).
1 finding from 1 review
Death (all causes) · previously untreated patients with mRCC
Interferon‐α plus bevacizumab showed no clear difference in 1‐year mortality median compared with standard targeted therapies (low certainty).
1 finding from 1 review
Quality of life · previously untreated patients with mRCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α plus bevacizumab showed no clear difference in adverse events (grade ≥ 3) compared with standard targeted therapies (low certainty).
1 finding from 1 review
1‐year mortality · previously untreated patients with mRCC
Vaccine treatment showed no clear difference in 1‐year mortality compared with standard therapies (low certainty).
1 finding from 1 review